Go to the page content
2 min. read

Life's a balancing act – life, work, and type 2 diabetes

The continued search for balance

Health doesn't exist in a vacuum. This might sound obvious, but it's worth reflecting that health comes alongside everything else in your life. You’re constantly juggling many responsibilities from one moment to the next, striving to find the right balance between work, family, social commitments and everyday routines. Living with type 2 diabetes is another thing to juggle, but it shouldn’t get in the way of living your life.

With type 2 diabetes, your body may not respond effectively to a naturally occurring hormone called Glucagon-like peptide 1 (GLP-1)1. GLP-1 increases insulin levels when it's needed, thereby lowering blood sugar levels2. GLP-1 can also reduce food consumption, body weight and increase satiety2-4. Researchers are also looking into the role of GLP-1 in the risk of cardiovascular events, such as heart disease and stroke5-12.

It can be hard for someone with type 2 diabetes to be in tune with their body when it doesn’t respond as well as it should to GLP-1. But, what if your body worked in partnership with you, leaving you more free to focus on other things in life rather than type 2 diabetes?

The Perfect Partner

When your body works in partnership, managing type 2 diabetes can become one less thing to juggle. Whether you are living with type 2 diabetes or care for someone who is – speak to your doctor about treatment options.


  1. Salehi M, Aulinger B, Prigeon RL, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010; 59:1330-1337.
  2. Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30:72-130.
  3. Shah M and Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014; 15:181-187.
  4. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101:515-520.
  5. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:311-322.
  6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375:1834-1844.
  7. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394:121-130.
  8. Bellastella G, Maiorino MI, Longo M, et al. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta- Analysis. Stroke. 2020; 51:666-669.
  9. Barkas F, Elisaf M and Milionis H. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. Eur J Neurol. 2019; 26:559-565.
  10. Clinicaltrials.gov. A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL). Available at: https://clinicaltrials.gov/ct2/show/NCT03914326. Last accessed: January 2024.
  11. ClinicalTrials.gov. A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE). Available at: https://clinicaltrials.gov/ct2/show/NCT04560998. Last accessed: January 2024.
  12. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389(24):2221-2232.

Related articles

GLP 1 treatment and how it works

GLP 1 treatment and how it works

Glucagon-like peptide 1 (GLP-1) is a naturally occurring hormone in the body. Although its production is inhibited in people with type 2 diabetes, its function remains possible.